Episode Details

This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), from prognostic marker to clinical endpoint. Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the potential of MRD as a surrogate endpoint in AML, while Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, presents supporting evidence from large registry analyses.

Amin Turki, MD, PhD, Ruhr-University Hospital Bochum and University Hospital Essen, Essen, Germany, highlights the integration of MRD into risk stratification, while Wendy Stock, MD, University of Chicago Medical Center, Chicago, IL, reviews MRD detection methods, emerging technologies, and practical implementation in ALL.